Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Pharma Stocks Weighed Down by Competition, Generic Pressure
by Zacks Equity Research
Although pharma and biotech sectors rebounded in 2017 and started 2018 on an optimistic note, drug companies may find it a bit difficult to justify their high prices.
Can New Approvals Help Mylan Stock Turn Around in 2018?
by Zacks Equity Research
Mylan (MYL) faced challenging conditions in 2017 but 2018 is expected to be better driven by new product launches.
Pharmaceutical Industry Outlook - March 2018
by Zacks Equity Research
The year 2017 was rewarding for pharma and biotech stocks, with the sector witnessing some positive developments that led to a much-awaited recovery.
Mylan (MYL) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Mylan???s (MYL) mixed Q4 results show earnings beat but revenues miss on pricing pressure and weak EpiPen sales.
Will Mylan (MYL) Disappoint Investors This Earnings Season?
by Zacks Equity Research
During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.
United Therapeutics (UTHR) Q4 Earnings Decline on High Costs
by Zacks Equity Research
United Therapeutics' (UTHR) earnings per share decline in Q4 due to higher operating costs. Shares sink almost 10%.
Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Momenta (MNTA) delivers better-than-expected fourth-quarter results on the back of an upfront payment from CSL.
Teva's Problems Continue to Mount With No Relief in Sight
by Zacks Equity Research
Teva (TEVA) faces significant challenges including rapid erosion in sales of Copaxone and pricing erosion in the U.S. generics business.
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Here's Why Teva Pharma Stock Is Soaring Today
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) gained more than 10% in early morning trading Thursday after news emerged Wednesday that Warren Buffett's Berkshire Hathaway (BRK.B) took a massive stake in the struggling drugmaker during the fourth quarter.
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment
by Zacks Equity Research
J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Teva Stock Falls as Novartis Brings Another Copaxone Generic
by Zacks Equity Research
Teva's (TEVA) shares fall as Novartis launches the second generic version of the 40 mg formulation of Copaxone
Generic Drugmakers to Dump as Teva's Woes Continue in 2018
by Zacks Equity Research
The generic industry is facing several challenges pulling down several companies including Teva (TEVA).
Teva (TEVA) Q4 Earnings Top, Stock Tanks on Weak 2018 View
by Zacks Equity Research
Teva's (TEVA) fourth-quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate.
Teva (TEVA) Q4 Earnings & Sales Beat, 2018 View Disappoints
by Zacks Equity Research
Teva's (TEVA) fourth quarter earnings and sales beat expectations. However, the 2018 sales and earnings outlook falls short of consensus estimate. Stock crashes in pre-market trading.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.
Teva Completes Sale of Women's Health Segment for $703M
by Zacks Equity Research
Teva Pharmaceutical (TEVA) sells woman health specialty products for cash consideration of $703 million.
Amgen's Migraine Drug Hits Primary Endpoint in Phase IIIb
by Zacks Equity Research
Amgen's (AMGN) antibody Aimovig meets all primary and secondary endpoints in a phase IIIb study on patients with episodic migraine, who have failed multiple prior preventive treatments.
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
by Zacks Equity Research
Teva's (TEVA) two phase III studies evaluating the subcutaneous formulation of its asthma injection, Cinqair (reslizumab) fail to meet primary endpoints.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
by Zacks Equity Research
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Parkinson's Disease Space Again Under Spotlight This Week
by Zacks Equity Research
Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU
by Zacks Equity Research
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
by Zacks Equity Research
Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.
New Strong Sell Stocks for December 20th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Teva's Migraine Candidate Gets Priority Review From FDA
by Zacks Equity Research
Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA